Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Merck May Sell Animal Drug Assets Before Merger

By Pharmaceutical Processing | June 4, 2009

WHITEHOUSE STATION, N.J. (AP) — Merck & Co. is considering selling some of its veterinary medicine assets or the animal health business of Schering-Plough Corp., as it prepares to acquire its New Jersey neighbor. Merck executives said as much when they announced the $41.1 billion deal on March 9. As the two companies move closer to the deal’s expected fourth-quarter closing, they are exploring their options for divesting either business, Merck spokeswoman Amy Rose said Wednesday. “There haven’t been any decisions at this point,” she said. Whitehouse Station, N.J.-based Merck has a 50-50 partnership with France’s Sanofi-Aventis SA in a business called Merial. It sells some popular pet medicines — flea-and-tick blocker Frontline and chewable heartworm preventer Heartgard — plus Ivomec, which kills parasites in hogs and cattle. The venture had $684 million in first-quarter sales. Kenilworth, N.J.-based Schering-Plough sells more than 15 animal medicine products, including antibiotics, fertility treatments and a number of vaccines for livestock; de-worming treatments for multiple animals; vaccines and treatments for ear infections and diabetes for dogs and cats, and the HomeAgain pet recovery system. The unit had sales of $630 million in the first quarter. “There are a number of factors that could influence an ultimate decision,” Rose said. Those include whether federal antitrust regulators might find there would be too much overlap in the two businesses, and whether any terms of Merck’s joint venture agreement with Sanofi-Aventis could preclude competition from the Schering-Plough products.

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards